Elequin Capital’s Pacira BioSciences PCRX Stock Holding History

Elequin Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$609	Buy	24 +9	+60%	+$213	﹤0.01%	600
2026 Q1	$339	Sell	15 -39	-72%	-$867	﹤0.01%	589
2025 Q4	$1.4K	Buy	+54	New	+$1.28K	﹤0.01%	365
2025 Q3	–	Sell	-39	Closed	-$932	–	320
2025 Q2	$932	Buy	+39	New	+$983	﹤0.01%	341
2025 Q1	–	Sell	-4	Closed	-$75	–	559
2024 Q4	$75	Sell	4 -243	-98%	-$4.27K	﹤0.01%	493
2024 Q3	$3.72K	Buy	+247	New	+$4.22K	﹤0.01%	304
2024 Q2	–	Sell	-7	Closed	-$205	–	307
2024 Q1	$205	Buy	+7	New	+$215	﹤0.01%	223
2023 Q3	–	Sell	-69	Closed	-$2.77K	–	557
2023 Q2	$2.77K	Buy	+69	New	+$2.85K	﹤0.01%	420
2022 Q3	–	Sell	-212	Closed	-$12K	–	645
2022 Q2	$12K	Sell	212 -23	-10%	-$1.51K	﹤0.01%	223
2022 Q1	$18K	Buy	+235	New	+$15.7K	﹤0.01%	128

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elequin Capital's PCRX Position: Q2 2026 in Review

Elequin Capital increased its Pacira BioSciences (PCRX) stake by 60% in Q2 2026, buying an estimated $213 and bringing the position to 24 shares worth $609. The position accounts for ﹤0.01% of the portfolio, ranked #600.

Elequin Capital first reported a position in PCRX in Q1 2022 and has held it in 10 quarters since. The position peaked at $18K in Q1 2022. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Elequin Capital held 24 shares of Pacira BioSciences worth $609 as of Q2 2026.
Elequin Capital bought 9 Pacira BioSciences shares in Q2 2026, an estimated $213.
Pacira BioSciences made up ﹤0.01% of Elequin Capital's portfolio in Q2 2026, its #600 holding.
Elequin Capital first reported a position in Pacira BioSciences in Q1 2022 and has held it in 10 quarters since.
Elequin Capital's Pacira BioSciences position peaked at $18K in Q1 2022.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.